Statera Biopharma
(OTC) STAB
Statera Biopharma Financials at a Glance
Market Cap
$7,100
Revenue (TTM)
$3.69M
Net Income (TTM)
$95.43M
EPS (TTM)
$0.00
P/E Ratio
0.00
Dividend
$0.00
Beta (Volatility)
-105.26 (Low)
Dividend
$0.00
Beta (Volatility)
-105.26 (Low)
Price
$0.00
Volume
104,789
Open
$0.00
Price
$0.00
Volume
104,789
Open
$0.00
Previous Close
$0.00
Daily Range
$0.00 - $0.00
52-Week Range
$0.00 - $0.01
Dividend
$0.00
Beta (Volatility)
-105.26 (Low)
Price
$0.00
Volume
104,789
Open
$0.00
Previous Close
$0.00
Daily Range
$0.00 - $0.00
52-Week Range
$0.00 - $0.01
STAB News
STAB: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Statera Biopharma
Industry
Biotechnology
Sector
Health CareEmployees
16
CEO
Michael Kevin Handley, MBA
Website
www.staterabiopharma.comHeadquarters
Fort Collins, CO 80526, US
STAB Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
0%
Return on Capital
-10%
Return on Assets
-8%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$7.10K
Shares Outstanding
71.42M
Volume
104.79K
Short Interest
0.00%
Avg. Volume
8.85K
Financials (TTM)
Gross Profit
$488.31K
Operating Income
$98.34M
EBITDA
$170.65M
Operating Cash Flow
$28.19M
Capital Expenditure
$182.97K
Free Cash Flow
$28.38M
Cash & ST Invst.
$1.98M
Total Debt
$16.26M
Statera Biopharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonCurrently no data to display.
Quarterly Performance
Revenue
$670.47K
+183.5%
Gross Profit
$501.12K
+315.5%
Gross Margin
74.74%
N/A
Market Cap
$7.10K
N/A
Market Cap/Employee
$154.35
N/A
Employees
46
N/A
Net Income
$5.16M
+59.4%
EBITDA
$1.35M
+85.7%
Quarterly Fundamentals
Net Cash
$6.90M
+5.3%
Accounts Receivable
$361.43K
+150.6%
Inventory
$105.64K
N/A
Long Term Debt
$686.14K
-95.0%
Short Term Debt
$6.72M
+118.1%
Return on Assets
-8.24%
N/A
Return on Invested Capital
-9.91%
N/A
Free Cash Flow
$801.52K
+94.5%
Operating Cash Flow
$801.52K
+94.5%